Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2181 to 2190 of 2579 total matches.
Tranexamic Acid (Lysteda) for Treatment of Menorrhagia
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010 (Issue 1342)
Table 1. Pharmacology
ADVERSE EFFECTS — Tranexamic acid is contraindicated in women with a history ...
The FDA has approved the use of tranexamic acid (Lysteda – Ferring), an oral antifibrinolytic, for treatment of menorrhagia. Tranexamic acid has been used for this purpose in Europe for decades, and is available without a prescription in some countries. It has been available in the US since 1987 for use with coagulation factors in patients with hemophilia undergoing dental extractions.
Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
fever, myalgia,
arthralgia) with oral formulations
and within 1-3 days of
infusion, most frequently ...
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e112-4 doi:10.58347/tml.2024.1706b | Show Introduction Hide Introduction
Xanomeline/Trospium (Cobenfy) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
greater with xanomeline/trospium than
with placebo in EMERGENT-2, but not in EMERGENT-3.1,2
Interim data ...
The FDA has approved Cobenfy (BMS), an oral
fixed-dose combination of the muscarinic agonist
xanomeline and the peripheral muscarinic antagonist
trospium chloride, for treatment of schizophrenia in
adults. It is the first antipsychotic drug to be approved
in the US for treatment of schizophrenia that does not
block dopamine receptors. This is the first approval
for xanomeline; trospium has been available for many
years for treatment of overactive bladder.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):177-9 doi:10.58347/tml.2024.1715a | Show Introduction Hide Introduction
Drugs That Cause Pulmonary Toxicity
The Medical Letter on Drugs and Therapeutics • Sep 21, 1990 (Issue 827)
, hypersensitivity pneumonitis
Amiodarone (Cordarone)
1
Occasional High doses
Aspirin see Salicylates
Atracurium ...
Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr et al, Am Rev Respir Dis, 133:321, 488, 1986). Pulmonary effects that are part of a generalized reaction or are indirect effects of drugs - on respiratory muscles, for example, or on the immune system - are not included here.
Three New Drugs for Hyperlipidemia
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
CHOLESTEROL- AND TRIGLYCERIDE-LOWERING DRUGS
Drug Usual daily dosage Cost
1
HMG-CoA Reductase Inhibitors ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Two New Drugs for Colon Cancer
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004 (Issue 1184)
to progression (4.1 vs. 1.5 months) (D Cunningham et al,
Proc Am Soc Clin Oncol 2003; 22:252, abstract 1012 ...
Cetuximab (Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab (Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved by the FDA for treatment of patients with metastatic colorectal cancer. Cetuximab is approved for treatment of patients with EGFR-expressing tumors, either in combination regimens with irinotecan (Camptosar)when the cancer has progressed on irinotecan-based therapy, or as monotherapy for those who cannot tolerate irinotecan. Bevacizumab is approved...
Duloxetine (Cymbalta): A New SNRI for Depression
The Medical Letter on Drugs and Therapeutics • Oct 11, 2004 (Issue 1193)
available in the US
1
; the conclusion was that it might
be more effective than a selective serotonin ...
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), has been approved by the FDA for treatment of major depressive disorder in adults, and more recently for diabetic peripheral neuropathy as well. The Medical Letter will review its role in diabetic neuropathy in a future issue.
Palladone for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
for treatment of chronic pain,
often in combination with adjuvant analgesics.
1
Milligram for milligram, oral ...
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride (Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms (Dilaudid, and others).
Dehydroepiandrosterone (DHEA)
The Medical Letter on Drugs and Therapeutics • May 09, 2005 (Issue 1208)
/d stabilized or improved symptoms and reduced corticosteroid requirements for up
to 1 year.
6,7 ...
Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has been used by athletes as a substitute for anabolic steroids. DHEA is banned by the International Olympic Committee, National Collegiate Athletic Association, National Football League and other sports organizations, but it was specifically exempted from becoming a controlled substance in the Anabolic Steroid Control Act of 2004.
Acupuncture
The Medical Letter on Drugs and Therapeutics • May 08, 2006 (Issue 1234)
of needles, acupoints can be stimulated by
heat, electrical current or just pressure.
1,2
MECHANISM ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.